RNA240920C41000
- 2.04
- +0.24+13.33%
Avidity Biosciences Newsroom
Cantor Fitzgerald Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $96
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Avidity Biosciences Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target
Wells Fargo Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $75
Barclays Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $63
Barclays Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $63
Analysts' Top Healthcare Picks: Addex Therapeutics (ADXN), Avidity Biosciences (RNA)
Avidity Biosciences Price Target Cut to $53.00/Share From $54.00 by Evercore ISI Group
Avidity Biosciences Analyst Ratings
Evercore ISI Group Maintains Outperform on Avidity Biosciences, Lowers Price Target to $53
Evercore Maintains Avidity Biosciences(RNA.US) With Buy Rating, Cuts Target Price to $53
Evercore ISI Trims Price Target on Avidity Biosciences to $53 From $54, Keeps Outperform Rating
BofA Securities Initiates Avidity Biosciences(RNA.US) With Buy Rating, Announces Target Price $51
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Promising Phase 1/2 Results for Avidity Biosciences Reinforce Buy Rating With New Price Objective
TD Cowen Maintains Avidity Biosciences(RNA.US) With Buy Rating, Maintains Target Price $56
Leerink Partners Maintains Avidity Biosciences(RNA.US) With Buy Rating, Raises Target Price to $64
Avidity Biosciences Analyst Ratings
Needham Reiterates Buy on Avidity Biosciences, Maintains $60 Price Target